Table 2.
Synergy evaluation of combinations consisting of dUSTBβPs and novobiocin or rifampicin against wild-type P. aeruginosa PAO1.
| dUSTBβP | Antibiotic | MICdUSTBβP [MICcombo] (μg/mL) | MICantibiotic [MICcombo] (μg/mL) | FICI | Interpretation | Absolute MICa antibiotic (μg/mL) | Potentiationb |
|---|---|---|---|---|---|---|---|
| 1 | Novobiocin | >128 [8] | 1,024 [128] | 0.125 < x < 0.188 | Synergy | 128 | 8-fold |
| Rifampicin | >128 [16] | 16 [4] | 0.25 < x < 0.375 | Synergy | 8 | 2-fold | |
| 2 | Novobiocin | >128 [8] | 1,024 [128] | 0.125 < x < 0.188 | Synergy | 128 | 8-fold |
| Rifampicin | >128 [16] | 16 [4] | 0.25 < x < 0.375 | Synergy | 8 | 2-fold | |
| 3 | Novobiocin | 128 [8] | 1,024 [32] | 0.094 | Synergy | 32 | 32-fold |
| Rifampicin | 128 [8] | 16 [0.25] | 0.078 | Synergy | 0.25 | 64-fold |
a
MIC of antibiotic in the presence of 8 μg/mL (6 μM) dUSTBβP.
b
Degree of antibiotic potentiation in the presence 8 μg/mL (6 μM) dUSTBβP.